Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP and CCO | January 06, 2021 | January 09, 2021 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 01, 2026 | July 06, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date January 06, 2021 · Filed January 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,059 |
Ending reported balance
After 2021-01-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-01-06 · Exercise / conversion · Acquired 2,722 · Balance 9,179 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2021-01-06 · Sale · Disposed 1,120 · Balance 8,059 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,167 |
Reported balance
After 2021-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-06 · Exercise / conversion · Disposed 2,722 · Balance 8,167 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.
IONIS PHARMACEUTICALS INC
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30 | Direct | 5,369 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 9,451 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 2,301 · Balance 9,451 F3: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
F3: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F4: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,798 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 19,798 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AKCEA THERAPEUTICS, INC.
Report date October 12, 2020 · Filed October 13, 2020
Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12 | Direct | 0 |
Reported balance
After 2020-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2019 Filed Dec 13, 2019 22:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 22,500 | $19.98 | $449,550.00 |
DisclosureSEC source: 0001209191-19-060476 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 876 shares of the Issuer's common stock acquired by the reporting person on November 15, 2017 pursuant to an employee stock purchase program. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 23:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,521 | $0.00 Strike: $35.86 | $0.00 |
DisclosureSEC source: 0001209191-19-060101 · doc4.xml · derivative · entry 4 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,479 Underlying: Common Stock · 14,521 shares Expires 2027-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 23:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,502 | $50.05 | $175,285.96 |
DisclosureSEC source: 0001209191-19-060101 · doc4.xml · nonDerivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,623 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 23:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 11,019 | $50.60 | $557,506.31 |
DisclosureSEC source: 0001209191-19-060101 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,125 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 23:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 14,521 | $35.86 | $520,723.06 |
DisclosureSEC source: 0001209191-19-060101 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053493 · doc4.xml · derivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 877 | $39.65 | $34,773.05 |
DisclosureSEC source: 0001209191-19-053493 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,623 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053493 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 20, 2019 Filed Sep 23, 2019 17:12 UTC | AKCEA THERAPEUTICS, INC. AKCA · Entity 145982 | GrantStock Option (right to buy) · Derivative | 53,000 | $0.00 Strike: $22.46 | $0.00 |
DisclosureSEC source: 0001209191-19-050475 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2029-09-19 F1 · derivative.exercise_date: The shares vest over a four year period in equal annual installments beginning on September 20, 2019. Read SEC document |
| April 29, 2019 Filed May 1, 2019 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 16,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026847 · doc4.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,827 Underlying: Common Stock · 16,827 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2019 Filed May 1, 2019 22:01 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 59,042 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001209191-19-026847 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,042 Underlying: Common Stock · 59,042 shares Expires 2029-04-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 29, 2020. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-027361 · doc4.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning October 15, 2019. Read SEC document |
| October 15, 2018 Filed Oct 24, 2018 20:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0000899243-18-027361 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-10-15 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 22:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001415889-18-000657 · form4-04202018_030428.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-04-17 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 22:14 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 93,750 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001415889-17-001471 · form4-09082017_030923.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2027-09-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on September 7, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 21:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $35.86 | $0.00 |
DisclosureSEC source: 0001415889-17-000528 · form4-03312017_020314.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP AND CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-03-28 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option vest and become exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.